This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Dengvaxia
- Generic Name
- Cyd dengue virus serotype 2 live (attenuated) antigen
- DrugBank Accession Number
- DB15522
- Background
Not Available
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur 2022-06-08 Not applicable EU 
Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur 2022-06-08 Not applicable EU Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur 2022-06-08 Not applicable EU Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (100000 [CCID_50]/0.5mL) + Cyd dengue virus serotype 1 live (attenuated) antigen (100000 [CCID_50]/0.5mL) + Cyd dengue virus serotype 3 live (attenuated) antigen (100000 [CCID_50]/0.5mL) + Cyd dengue virus serotype 4 live (attenuated) antigen (100000 [CCID_50]/0.5mL) Injection, powder, lyophilized, for suspension; Kit Subcutaneous Sanofi Pasteur Inc. 2019-05-01 Not applicable US 
Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur 2022-06-08 Not applicable EU Dengvaxia Cyd dengue virus serotype 2 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 1 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 3 live (attenuated) antigen (0.7156818821 CCID50) + Cyd dengue virus serotype 4 live (attenuated) antigen (0.7156818821 CCID50) Injection, powder, for suspension Subcutaneous Sanofi Pasteur 2022-06-08 Not applicable EU DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION Cyd dengue virus serotype 2 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 1 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 3 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 4 live (attenuated) antigen (5.25 log10 CCID50/dose) Injection, powder, for suspension Subcutaneous SANOFI-AVENTIS SINGAPORE PTE. LTD. 2016-10-11 Not applicable Singapore 
DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION Cyd dengue virus serotype 2 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 1 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 3 live (attenuated) antigen (5.25 log10 CCID50/dose) + Cyd dengue virus serotype 4 live (attenuated) antigen (5.25 log10 CCID50/dose) Injection, powder, for suspension Subcutaneous SANOFI-AVENTIS SINGAPORE PTE. LTD. 2016-11-10 Not applicable Singapore
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FH5SVG7GLC
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Dengue Fever / Dengue Hemorrhagic Fever / Human Papillomavirus Disease 2 3 Terminated Prevention Dengue Fever / Dengue Hemorrhagic Fever 1 2 Completed Prevention Dengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus 1 2 Completed Prevention Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus 1 Not Available Completed Not Available Dengue Fever 1 Not Available Recruiting Not Available Dengue Virus Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for suspension Subcutaneous Injection, powder, lyophilized, for suspension; kit Subcutaneous Injection, powder, for suspension Subcutaneous 5.25 log10 CCID50/dose - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 09, 2019 19:53 / Updated at June 12, 2020 16:53